<DOC>
	<DOCNO>NCT02354105</DOCNO>
	<brief_summary>The primary purpose ass effectiveness certolizumab pegol patient axial spondyloarthritis routine clinical practice .</brief_summary>
	<brief_title>A Study Assess Effectiveness Certolizumab Pegol Patients With Axial Spondyloarthritis Daily Life</brief_title>
	<detailed_description />
	<mesh_term>Spondylarthritis</mesh_term>
	<mesh_term>Certolizumab Pegol</mesh_term>
	<criteria>The patient personally sign dated Patient Data Consent Form ( PDCF ) prior Visit 2 . No data enter electronic Documentation form ( eDF ) prior signature PDCF . The patient must clinical diagnosis active axial spondyloarthritis ( axSpA ) , [ ankylose spondylitis ( AS ) nonradiographic axial spondyloarthritis ( nraxSpA ) ] accord diagnostic criterion use physician routine clinical practice . The decision prescribe Certolizumab Pegol ( CZP ) make physician independent patient 's participation NIS . The patient must newly prescribe CZP accord local regulation guideline ( eg , Bath Ankylosing Spondylitis Disease Activity Index ( BASDAI ) &gt; =4 ) . Treatment accord instruction Summary Product Characteristics ( SmPC ) patient consider treat physician reliable capable adhere observational plan ( eg , able understand complete questionnaire ) . If patient participate ongoing investigational study , he/she able take part study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Axial Spondyloarthritis</keyword>
	<keyword>Radiographic Axial Spondyloarthritis</keyword>
	<keyword>Non-radiographic Axial Spondyloarthritis</keyword>
	<keyword>Ankylosing spondylitis</keyword>
	<keyword>Diagnosis</keyword>
	<keyword>Cimzia</keyword>
	<keyword>CZP</keyword>
	<keyword>Certolizumab Pegol</keyword>
	<keyword>CDP870</keyword>
</DOC>